Wyeth

Affinivax, Inc.

Genocea Biosciences, Inc.

Dana-farber-cancer Institute Inc.

Harvard College

University System of Maryland

Wyeth Holdings Corporation

George Rainer Siber

Peter R Paradiso

William P Hausdorff

Jill Hackell

Stephen Paul Lockhart

Richard Malley

Teresa J Broering

Yingjie Lu

Fan Zhang

A Krishna Prasad

Jessica Baker Flechtner

Mojca Skoberne

Shite Sebastian

Velupillai Puvanesarajah

Deborah Long

Francis Michon

Donna Ambrosino

Alan S Cross

David M Knipe

Raphael Simon

Sharon Tennant

Robert W Finberg

Robert C Liddington

Adolf Hoess

Jessica Flechtner

Alan Cross

Technologies for the prevention and/or treatment of pneumococcal infections.

Multivalent pneumococcal vaccines

Methods of immunizing older adult subjects againstinfection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

Pneumococcal dosing regimen

Technologies for the prevention and/or treatment of nosocomial infections.

Immunogenic compositions

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.

Process for preparing pneumococcal polysaccharide-protein conjugates

Methods of immunizing older adult subjects againstinfection are provided. Provided methods comprise immunization of na&#xef;ve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.

Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Methods of immunizing older adult subjects againstinfection are provided. Provided methods comprise immunization of naive adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprisingserotype 1 polysaccharide covalently linked to a carrier protein, the method including partial de-O-acetylation of the polysaccharide by mild hydrolysis in an alkaline pH buffer.

Multivalent pneumococcal polysaccharide-protein conjugate composition

Growing community of inventors

New York, NY, United States of America

George Rainer Siber